EANO Meeting - Saturday, October 18, 2025
Note that the programme is subject to change and will be continuously updated.
All times below refer to Central European Summer Time (CEST).
08:00-09:00 hrs
Meet the Experts (ME03) | The Brain Necrosis Dilemma: Is Imaging Sufficient for Treatment Decisions?
Chairs: tbc
ME03.1 Is imaging sufficient for diagnosis? A neuroradiologist perspective
tbc
ME03.2 Finding Markers for Radionecrosis: A Neuropathologist’s Approach
Abigail Suwala, Germany
ME03.3 Radiation and risk of radionecrosis: can we avoid it?
Anca Grosu, Germany
ME03.4 When and how I treat radionecrosis: the medical oncologist perspective
Evangelia Razis, Greece
Chairs: tbc
JS06.1 What can a supporting agency such as EORTC do for you?
Michael Weller, Switzerland
JS06.2 Clinical trial management: Steering Committee, the Medical Monitor and the Data Monitoring Committee
tbc
JS06.3 EORTC-2227 (LEGATO): Lomustine with and without reirradiation for first progression of glioblastoma: a randomized phase III study
Tomas Kazda, Czech Republic
JS06.4 EORTC-2334 (LUMEN-1): 177Lu-DOTATATE for recurrent MENingioma: a randomized phase II study
Emeline Tabouret, France
JS06.5 EORTC 2427 (VIGOR): Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled randomized phase III study
Marta Padovan, Italy
JS06.6 EORTC-2013 (GLIO-RARE): Observational study for assessing treatment and outcome of patients with primary brain tumours diagnosed according to cIMPACT-NOW recommendations and the 2021 WHO classification
Maximilan Mair, Austria
Chairs: tbc
ME04.1 Economic impact of glioma survivorship
Tobias Walbert, United States
ME04.2 Family functioning in neuro-oncology
Paula Sherwood, United States
ME04.3 Implementing Family-Focused Care and Person-Centeredness in Clinical Neuro-oncology
Karin Piil, Denmark
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Chairs: Anna Berghoff, tbc
JS07.1 Innovative CAR T cell designs for pediatric and adult brain tumors
Robbie Majzner, United States
JS07.2 B7H3 CAR T cells for ependymoma and diffuse midline glioma
Nick Vitanza, United States
JS07.3 Vaccines targeting H3-altered gliomas
Katharina Sahm, Germany
JS07.4 Modulation of the immunosuppressive microenvironment of pediatric high-grade gliomas
Dannis van Vuurden, Netherlands
Chairs: tbc
KS03.1 Cranioencephalic functional lymphoid units in glioblastoma
Celia Dobersalske, Germany
KS03.2 Venous-plexus-associated lymphoid hubs support meningeal humoral immunity
Dorothy Sipkins, United States
KS03.3 Adult skull bone marrow is an expanding and resilient haematopoietic reservoir
Bong-Ihn Koh, Germany
Chairs: tbc
PD02.1 Building a Strong Group: Adapting to Changing Roles and Hierarchies
Roel Verhaak, United States
PD02.2 Networking for Success: Strategies to Build Meaningful Connections
tbc
PD02.3 Yes or No? How to Tackle Workload Overload and Make Smart Decisions
Ghazaleh Tabatabai, Germany
PD02.4 Bridging the Gap: How to Effectively Communicate with Industry
Martin van den Bent, Netherlands
10:45-11:15 hrs | COFFEE BREAK
11:15-12:45 hrs
Chairs: tbc
OS06.1 Maximizing the Benefits of Palliative Care – Early or Late Integration?
Caroline Hertler, Switzerland
OS06.2 LGBTQ inclusive end-of-life care’
Max Kleijberg, Sweden
OS06.3 Advanced care planning in brain tumors – when is the right time?
Johan Koekkoek, Netherlands
OS06.4 Core Outcome Set for Palliative Care Interventions for Adults living with Primary CNS Cancer
Heather Leeper, United States
12:45-14:15 hrs | LUNCH BREAK
13:00-14:00 hrs
14:15-15:45 hrs
Chairs: tbc
OS08.1 Should supramarginal resection be guided by imaging?
Nathalie Albert, Germany
OS08.2 Interim analysis of randomised study on supramarginal resection of glioblastoma
Alireza Mansouri, United States
OS08.3 Can patients with metastasis benefit from supramaximal resection?
Matthew Dankner, Canada
OS08.4 Onco-functional balance in supramarginal resection
Jasper Gerritsen, Netherlands
Chairs: tbc
OS09.1 Classifiy of IDH mutant gliomas for treatment decsions (Continuous Grading Coefficient, CGC)
Adelheid Wöhrer, Austria
OS09.2 Effects of IDH inhibition on lineage differentiation
Itay Tirosh, Israel
OS09.3 Metabolomic insights in the biology of IDH-mutant gliomas
tbc
OS09.4 The landscape of IDH as a therapeutic target
Lukas Bunse, Germany
Chairs: tbc
PC01.1 PCV vs. Temozolomide in IDH-mutant glioma - Pro PCV
Mehdi Touat, France
PC01.2 PCV vs. Temozolomide in IDH-mutant glioma - Pro TMZ
Anna Berghoff, Austria
PC01.3 Partial resection vs. biopsy in glioma - Pro partial resection
Alberto Gallotti, Italy
PC01.4 Partial resection vs. biopsy in glioma - Pro biopsy
Johnny Duerinck, Belgium
PC01.5 Striking Early: The Impact of Preoperative Radiosurgery on Brain Metastases
Raphael Bodensohn, Germany
PC01.6 Pre- vs. Postoperative stereotactic radiosurgery in brain metastases - Pro postoperative
Tomas Kazda, Czech Republic
15:45-16:00 hrs | BREAK
16:00-17:00 hrs
Chairs: tbc
ME05.1 Using translationally relevant cognitive testing in preclinical and clinical neuro-oncology research
Dorien Maas, Netherlands
ME05.2 Crossing over between immunology and neuro-oncology
Stephen Francis, United States
ME05.3 Systems biology in molecular neuro-oncology
Adil Mardinoglu, Sweden
ME05.4 Brain network topology and cognition in brain tumor patients
Charlotte Sleurs, Netherlands
Chairs: tbc
OS10.1 Epigenetics signatures predicting brain metastasis from lung cancer primary tumors and liquid biopsies
Gelareh Zadeh, Canada
OS10.2 Impact oft the microenvironment of brain metastases for therapy efficacy
Manuel Valiente, Spain
OS10.3 T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels (immunity 2024)
Matthia Karreman, Germany
OS10.4 Clinical efforts to identifiy relevant biomarkers for predicting brain mets (BrainStorm study)
tbc
Chairs: tbc
PD03.1 The surgeons perspective
Bogdana Suchorska, Germany
PD03.2 The radiooncologist perspective
Susan Short, United Kingdom
PD03.3 The imaging perspective
Antonella Castellano, Italy
PD03.4 The neurologist perspective
Amelie Darlix, France
Chairs: tbc